Enhance MD vs Maximus: Pricing, Compounds, and Pharmacy Sourcing
Enhance MD vs Maximus centers on price structure, compound options, pharmacy sourcing, and scale. Quick verdict: Enhance MD is the lower-cost entry with both semaglutide and tirzepatide available and flat-rate dosing; Maximus offers a single low flat monthly semaglutide price with U.S. pharmacy fulfillment and broader state availability.
See Enhance MD pricing and options
Key comparison at a glance
This comparison uses only the supplied evidence. Enhance MD advertises semaglutide starting at $49/first month and tirzepatide from $99 first month with flat-rate pricing that stays the same at every dose. Maximus lists semaglutide at $132.99/month, prescribed by licensed doctors and filled through trusted U.S. pharmacies.
| Criterion | Enhance MD | Maximus |
|---|---|---|
| Starting price | Semaglutide starting at $49/first month; tirzepatide from $99/first month | $132.99/month (semaglutide) |
| Pricing model | Flat-rate pricing: same price at every dose; introductory first-month rates apply | Low flat rate at $132.99/month; transparent monthly cost |
| Compound options | Both semaglutide and tirzepatide available on one platform | Focus on compounded semaglutide; tirzepatide availability not clearly published |
| Pharmacy sourcing | Compounded medications; regulatory note: not FDA-approved finished products | Compounded in U.S.-based pharmacies; prescriptions filled through trusted U.S. pharmacies |
| Scale and track record | 10,000+ patients treated | Smaller, newer platform with fewer public reviews |
Pricing and ongoing cost differences
Enhance MD promotes very low introductory pricing with semaglutide from $49/first month and tirzepatide from $99/first month, then applies a flat-rate ongoing price that stays the same at every dose. Maximus advertises a single flat-monthly semaglutide price at $132.99/month. Both operate on a direct-pay model and do not bill insurance. The evidence supplied notes that Enhance MD’s $49/$99 rates are first-month introductory prices and that ongoing flat-rate pricing is higher.
Compound availability and program scope
Enhance MD is one of the few platforms in this comparison to explicitly offer both compounded semaglutide and compounded tirzepatide on the same platform, which the source frames as useful for patients deciding between compounds. Maximus centers on compounded semaglutide in its Weight Loss Protocol; the source notes limited published detail on tirzepatide availability for Maximus.
Pharmacy sourcing, approvals, and regulatory notes
Maximus fills prescriptions through trusted U.S. pharmacies and emphasizes prescriptions approved by licensed doctors and free expedited shipping. Enhance MD also dispenses compounded medications; both sources include the regulatory note that compounded medications are not FDA-approved finished products and are not reviewed by FDA for safety, effectiveness or quality. Maximus additionally states program availability in all 50 states except Mississippi, while Enhance MD availability by state is not supplied in the evidence.
Check Enhance MD compound options
Scale, experience, and patient volume
Enhance MD reports treating more than 10,000 patients, which the source cites as meaningful real-world clinical volume. Maximus is described as a smaller, newer platform with a thinner public track record. If documented scale or public review volume matters to you, the supplied facts favor Enhance MD on track record.
What matters most: three distinctive differences
- Entry price: Enhance MD supplies the lowest first-month semaglutide and tirzepatide pricing in the sources provided.
- Compound choice: Enhance MD explicitly offers both semaglutide and tirzepatide; Maximus primarily documents semaglutide.
- Pharmacy sourcing and state availability: Maximus highlights U.S. pharmacy fulfillment and notes availability in all 50 states except Mississippi; Enhance MD emphasizes flat-rate dosing and 10,000+ patients treated.
Bottom line: Enhance MD vs Maximus
Enhance MD vs Maximus breaks down to whether you prioritize the lowest introductory price and dual-compound availability (Enhance MD) or a simple low flat monthly semaglutide program with U.S. pharmacy fulfillment and broader stated state coverage (Maximus). Both use compounded medications and direct-pay telemedicine models. Regulatory notes supplied state that compounded medications are not FDA-approved finished products.
Choose Enhance MD if you want the lowest documented first-month semaglutide pricing, access to tirzepatide on the same platform, flat-rate pricing that the source says stays the same at every dose, and a larger reported patient base.